Abstract
1. Almitrine bismesylate displays wide inter-subject variation in peak plasma concentrations and can induce peripheral polyneuropathy. 2. The phenotyped volunteer panel approach was used to examine whether almitrine oxidation displayed a genetic polymorphism of the debrisoquine/sparteine type. 3. There was no difference between poor and extensive metabolisers of debrisoquine with respect to the pharmacokinetics and metabolism of almitrine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Belec L., Larrey D., De Cremoux H., Tinel M., Louarn F., Pessayre D., Gherardi R. Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy. Br J Clin Pharmacol. 1989 Mar;27(3):387–390. doi: 10.1111/j.1365-2125.1989.tb05382.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bromet N., Courte S., Aubert Y., Baune A., Balem M. P., du Vignaud P. Pharmacokinetics of almitrine bismesylate: studies in patients. Eur J Respir Dis Suppl. 1983;126:363–375. [PubMed] [Google Scholar]
- Bromet N., Singlas E. Pharmacocinétique clinique du bismésilate d'almitrine. Presse Med. 1984 Oct 4;13(34):2071–2077. [PubMed] [Google Scholar]
- Campbell D. B., Gordon B., Taylor A., Taylor D., Williams J. The biodisposition of almitrine bismesylate in man: a review. Eur J Respir Dis Suppl. 1983;126:337–348. [PubMed] [Google Scholar]
- Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
- Gherardi R., Louarn F., Benvenuti C., Perrier M., Lejonc J. L., Schaeffer A., Degos J. D. Peripheral neuropathy in patients treated with almitrine dimesylate. Lancet. 1985 Jun 1;1(8440):1247–1250. doi: 10.1016/s0140-6736(85)92315-3. [DOI] [PubMed] [Google Scholar]
- MacLeod C. N., Thomas R. W., Bartley E. A., Parkhurst G. W., Bachand R. T. Effects and handling of almitrine bismesylate in healthy subjects. Eur J Respir Dis Suppl. 1983;126:275–289. [PubMed] [Google Scholar]
- Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
- Petit H., Leys D., Hurtevent J. F., Parent M., Caron J., Salomez J. L., Krivosic I. Neuropathies et almitrine. Quatorze cas. Rev Neurol (Paris) 1987;143(6-7):510–519. [PubMed] [Google Scholar]
- Tweney J. Almitrine bismesylate: current status. Bull Eur Physiopathol Respir. 1987 Aug;23 (Suppl 11):153s–163s. [PubMed] [Google Scholar]